Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Elite Pharma Inc (ELTP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 94,262
  • Shares Outstanding, K 788,800
  • Annual Sales, $ 9,640 K
  • Annual Income, $ 3,810 K
  • 36-Month Beta -0.38
  • Price/Sales 9.65
  • Price/Cash Flow 23.94
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/08/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0810 +47.53%
on 12/28/17
0.1450 -17.59%
on 01/11/18
+0.0295 (+32.78%)
since 12/15/17
3-Month
0.0560 +113.39%
on 10/27/17
0.1450 -17.59%
on 01/11/18
+0.0298 (+33.22%)
since 10/17/17
52-Week
0.0560 +113.39%
on 10/27/17
0.2495 -52.10%
on 05/15/17
-0.0524 (-30.48%)
since 01/17/17

Most Recent Stories

More News
Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies for an undisclosed extended-release generic product in co-development...

ELTP : 0.1195 (+1.36%)
Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has received...

ELTP : 0.1195 (+1.36%)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the second quarter...

ELTP : 0.1195 (+1.36%)
CORRECTING and REPLACING - Elite Pharmaceuticals, Inc.

In a release issued earlier today by Elite Pharmaceuticals, Inc. (OTCQB:ELTP), please note in the headline the conference call date should be "November 10" rather than "September 10" as previously issued....

ELTP : 0.1195 (+1.36%)
Elite Pharmaceuticals Files ANDA for Oxycodone Hydrochloride Extended Release

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic version...

ELTP : 0.1195 (+1.36%)
Elite Pharmaceuticals to Present ELI-200 (SequestOx(TM)) Data at PAINWeek 2017 National Conference

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today it will present data for ELI-200 at PAINWeek 2017 National Conference held in Las Vegas, Nevada, USA September 4 - 8,...

ELTP : 0.1195 (+1.36%)
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2018 Ended June 30, 2017 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the first quarter...

ELTP : 0.1195 (+1.36%)
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss First Quarter Financial Results on August 10, 2017

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that...

ELTP : 0.1195 (+1.36%)
Elite Announces New Development and License Agreement with SunGen Pharma LLC

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into...

ELTP : 0.1195 (+1.36%)
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies conducted in April of this year for an undisclosed generic...

ELTP : 0.1195 (+1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

See More

Key Turning Points

2nd Resistance Point 0.1309
1st Resistance Point 0.1252
Last Price 0.1195
1st Support Level 0.1134
2nd Support Level 0.1073

See More

52-Week High 0.2495
Fibonacci 61.8% 0.1756
Fibonacci 50% 0.1528
Fibonacci 38.2% 0.1299
Last Price 0.1195
52-Week Low 0.0560

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.